Teva Gets FTC Okay For Cephalon Deal After Reducing Its Generic Provigil Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal Trade Commission amends final order settling charges Teva’s acquisition of Cephalon would have been anticompetitive; agency cites Teva’s deal allowing Mylan to launch its generic Provigil 45 days early.
You may also be interested in...
Provigil Generic Exclusivity Decision “Eviscerates” Hatch-Waxman, FTC Says
In a strongly worded amicus brief filed in Mylan’s lawsuit against FDA, the Federal Trade Commission says it would have required different remedies in clearing Teva’s acquisition of Cephalon last year had it known the Israel-based firm would receive sole 180-day marketing exclusivity for modafinil.
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.